NCT00327522View on ClinicalTrials.gov

Safety and Immune Response Study of an Investigational Pneumococcal Vaccine.

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

June 30, 2006

Conditions
Prophylactic Pneumococcal Diseases
Interventions
BIOLOGICAL

pneumococcal vaccine

Trial Locations (1)

9000

GSK Investigational Site, Ghent

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY